Alder BioPharmaceuticals (ALDR) Misses Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Alder BioPharmaceuticals (ALDR) Misses Q1 EPS by 1c

Alder BioPharmaceuticals Reports First Quarter 2015 Financial and Operating Results

May 7, 2015 4:02 PM EDT

Alder Provides Update on Clinical Development Plan for ALD403 in Migraine Prevention

To Host Conference Call at 5:00pm EDT Today

BOTHELL, Wash., May 7, 2015 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (Nasdaq: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, Cushing's disease and autoimmune and inflammatory diseases, today provided recent corporate highlights and reported its financial results for the first quarter ended March 31, 2015.

"We are continuing our focus on expediting the development of ALD403... More